Research programme: dendritic cell vaccines - Immunomedics

Drug Profile

Research programme: dendritic cell vaccines - Immunomedics

Alternative Names: Dendritic cell vaccine - Immunomedics; Milatuzumab-Fab-A3B3

Latest Information Update: 08 Apr 2011

Price : $50

At a glance

  • Originator Immunomedics
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 04 Apr 2011 Pharmacodynamics data from preclinicals studies in Cancer presented at the 102nd Annual Meeting of American Association for Cancer Research (AACR-2011)
  • 04 Apr 2011 Preclinical development is ongoing in USA
  • 09 Feb 2005 This vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top